



ALEMBIC PHARMACEUTICALS LIMITED
 Read. Office: Alembic Road, Vadodara 390 003
 CIN:L24230GJ2010PLC061123
 Ph #: 0265 2280550 Fax #: 2280880
 Email : apl.investors@alembic.co.in Website: www.alembic-india.com

**UNAUDITED FINANCIAL RESULTS
 FOR THE PERIOD ENDED 30TH SEPTEMBER, 2014**

Rs. in lacs

	Particulars	STANDALONE					
		Quarter Ended			Period Ended		Year Ended
		September-14	June-14	September-13	September-14	September-13	March-14
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	(a) Net Sales / Income from Operations						
	Domestic	32,743	27,840	28,260	60,583	52,380	1,04,106
	Exports	21,562	20,525	20,397	42,087	39,122	80,793
	Total	54,305	48,365	48,657	1,02,670	91,502	1,84,899
	Less : Excise Duty	250	248	177	498	395	771
	Net Sales / Income from Operations	54,055	48,117	48,480	1,02,172	91,107	1,84,128
	(b) Other Operating Income	83	63	46	146	103	251
	Total Income from Operations	54,138	48,180	48,526	1,02,318	91,210	1,84,379
2	Expenses						
	(a) Decrease/(increase) in stock in trade and work in progress	(3,660)	(2,677)	(744)	(6,337)	(2,048)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	15,501	14,728	13,764	30,229	27,361	55,593
	(c) Purchase of traded goods	7,127	5,646	5,930	12,773	10,880	19,807
	(d) Employees' Cost	7,432	7,322	5,931	14,754	11,567	24,446
	(e) Marketing Expense	6,459	4,954	4,805	11,413	9,183	16,075
	(f) Research and Development Expense	2,770	2,754	3,121	5,524	5,190	10,510
	(g) Excise Duty	122	152	208	274	287	425
	(h) Other Expenditure	6,895	5,972	6,021	12,867	11,871	25,686
	Total Expenses	42,646	38,851	39,036	81,497	74,291	1,48,477
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	11,492	9,329	9,490	20,821	16,919	35,902
4	Other Income	14	18	20	32	22	319
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	11,506	9,347	9,510	20,853	16,941	36,221
6	Depreciation	1,084	1,071	985	2,155	1,938	4,049
7	Interest (Net)	92	56	257	148	404	981
8	CSR Expense	83	65	-	148	-	-
9	Net Profit from Ordinary Activities before Tax	10,247	8,155	8,268	18,402	14,599	31,191
10	Tax Expense						
	Less : Provision for Current Tax	2,135	1,714	1,739	3,849	3,066	6,700
	Less /Add : Provision for Deferred Tax Liability/(Assets)	(293)	293	146	-	203	663
11	Net Profit from Ordinary Activities after Tax	8,405	6,148	6,383	14,553	11,330	23,828
12	Paid up Equity Share Capital (Face value of share Rs. 2/-)	3,770	3,770	3,770	3,770	3,770	3,770
13	Reserves excluding Revaluation Reserve	-	-	-	-	-	59,199
14	Basic & Diluted EPS (Not Annualised)	4.46	3.26	3.39	7.72	6.01	12.64
A	PART- II						
1	Particulars of Shareholding						
	Public Shareholding						
	- Number of Shares	48777294	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
	Promoters and Promoter Group Shareholding						
	- Fully Non - Encumbered						
	- Number of Shares	139738620	139738620	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 30th September, 2014					
	Pending at the beginning of the quarter	NIL					
	Received during the quarter	5					
	Disposed of during the quarter	5					
	Remaining unresolved at the end of the quarter	NIL					



ALEMBIC PHARMACEUTICALS LIMITED
 Read:Office: Alembic Road, Vadodara 390 003
 CIN:L24230GJ2010PLC061123
 Ph #:0265 2280550 Fax #: 2280880
 Email : apl.investors@alembic.co.in Website: www.alembic-india.com

**UNAUDITED FINANCIAL RESULTS
 FOR THE PERIOD ENDED 30TH SEPTEMBER, 2014**

Rs. In Lacs

	Particulars	CONSOLIDATED					
		Quarter Ended			Period Ended		Year Ended
		September-14	June-14	September-13	September-14	September-13	March-14
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	(a) Net Sales / Income from Operations						
	Domestic	32,743	27,840	28,260	60,583	52,380	1,04,106
	Exports	22,132	21,773	20,507	43,905	39,265	82,735
	Total	54,875	49,613	48,767	1,04,488	91,645	1,86,841
	Less : Excise Duty	250	248	177	498	395	771
	Net Sales / Income from Operations	54,625	49,365	48,590	1,03,990	91,250	1,86,070
	(b) Other Operating Income	83	63	46	146	103	251
	Total Income from Operations	54,708	49,428	48,636	1,04,136	91,353	1,86,321
2	Expenses						
	(a) Decrease/(increase) in stock in trade and work in progress	(3,660)	(2,677)	(744)	(6,337)	(2,048)	(4,065)
	(b) Consumption of Raw Materials & Packing Materials	15,501	14,728	13,764	30,229	27,361	55,593
	(c) Purchase of traded goods	7,126	5,646	5,930	12,772	10,880	19,807
	(d) Employees' Cost	7,677	7,561	5,931	15,238	11,567	24,700
	(e) Marketing Expense	7,010	5,196	4,805	12,206	9,183	16,618
	(f) Research and Development Expense	3,109	2,953	3,382	6,062	5,622	11,643
	(g) Excise Duty	122	152	208	274	287	425
	(h) Other Expenditure	6,997	6,202	6,088	13,199	12,082	25,829
	Total Expenses	43,882	39,761	39,365	83,643	74,934	1,50,550
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	10,826	9,667	9,271	20,493	16,419	35,771
4	Other Income	14	18	20	32	22	319
5	Profit from Ordinary Activities before Interest, Depreciation, & Exceptional Items	10,840	9,685	9,291	20,525	16,441	36,090
6	Depreciation	1,084	1,071	985	2,155	1,938	4,049
7	Interest (Net)	104	56	257	160	404	981
8	CSR Expense	83	65	-	148	-	-
9	Net Profit from Ordinary Activities before Tax	9,569	8,493	8,049	18,062	14,099	31,060
10	Tax Expense						
	Less : Provision for Current Tax	2,136	1,735	1,739	3,871	3,068	6,847
	Less/(Add) : Provision for Deferred Tax Liability /(Assets)	(293)	293	146	-	203	663
11	Net Profit from Ordinary Activities after Tax	7,726	6,465	6,164	14,191	10,828	23,550
12	Share of Profit of Associates	1	2	-	3	-	-
13	Net Profit after Tax and share of profit of associates	7,727	6,467	6,164	14,194	10,828	23,550
14	Paid up Equity Share Capital (Face value of share ` 2/-)	3,770	3,770	3,770	3,770	3,770	3,770
15	Reserves excluding Revaluation Reserve	-	-	-	-	-	63,787
16	Basic & Diluted EPS (Not Annualised)	4.10	3.43	3.27	7.53	5.74	12.49
	PART- II						
A	Particulars of Shareholding						
1	Public Shareholding						
	- Number of Shares	48777294	48777294	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding						
	- Fully Non - Encumbered						
	- Number of Shares	139738620	139738620	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter Ended on 30th September, 2014					
	Pending at the beginning of the quarter						NIL
	Received during the quarter						5
	Disposed of during the quarter						5
	Remaining unresolved at the end of the quarter						NIL

Notes :

- 1 The above results, have been duly reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17)
- 3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 20th October, 2014

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com